Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ELOSULFASE ALFA

 
National Institutes of Health

Related topics

Related topics

7 relations
5 ML ELOSULFASE ALFA 1 MG/ML Injection5 ML ELOSULFASE ALFA 1 MG/ML Injection [Vimizim]Alpha-glucosidaseN-acetylgalactosamine-6-sulfatase
Expand

Broader (1)

GALNS protein, human

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Enzyme-Loaded Gel Core Nanostructured Lipid Carriers to Improve Treatment of Lysosomal Storage Diseases: Formulation and In Vitro Cellular Studies of Elosulfase Alfa-Loaded Systems
Mucopolysaccharidosis IVA (Morquio A) is a rare inherited metabolic disease caused by deficiency of the lysosomal enzyme N… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2017
2017
Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.
PURPOSE Elosulfase alfa is an enzyme replacement therapy for the treatment of Morquio A syndrome (mucopolysaccharidosis IVA), a… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2017
2017
Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa
BackgroundThis post hoc subanalysis examined outcomes in adult patients with Morquio A (mucopolysaccharidosis IVA) who received… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome.
Long-term efficacy and safety of elosulfase alfa enzyme replacement therapy were evaluated in Morquio A patients over 96weeks… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Review
2016
Review
2016
Role of elosulfase alfa in mucopolysaccharidosis IVA
Mucopolysaccharidosis type IVA (MPS IVA or Morquio A) is an autosomal recessive lysosomal storage disease which results in a… Expand
  • table 1
Is this relevant?
Review
2016
Review
2016
Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome).
INTRODUCTION Morquio A syndrome is a rare, autosomal recessive, lysosomal storage disorder caused by a deficiency in the enzyme N… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 3
Is this relevant?
2015
2015
Enzyme Replacement Therapies and Immunogenicity in Lysosomal Storage Diseases: Is There a Pattern?
Lysosomal storage diseases arise because of genetic mutations that result in nonfunctioning or dysfunctional lysosomal enzymes… Expand
Is this relevant?
Review
2014
Review
2014
Elosulfase alfa.
Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome, is an inherited, lysosomal storage disorder caused by… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE